Intestinal Research

Inflammatory Bowel Diseases
Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?: Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Evangelia Legaki, Maria Gazouli, Ioannis E. Koutroubakis; Intest Res. 2021;19(4):461-467. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00042
Cited By 4; Full text PubReader ePub Crossref - TDM PDF

Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis: Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, Tadashi Yokoyama, Masakazu Nagahori, Tomoki Inaba, Mitsuhiro Shikamura, Takayoshi Yamaguchi, Tetsuharu Hori, Philippe Pinton, Mamoru Watanabe, Toshifumi Hibi; Intest Res. 2021;19(4):448-460. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00026
Cited By 9; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis: Saransh Jain, Divya Namdeo, Pabitra Sahu, Saurabh Kedia, Peush Sahni, Prasenjit Das, Raju Sharma, Vipin Gupta, Govind Makharia, Lalit Dar, Simon PL Travis, Vineet Ahuja; Intest Res. 2021;19(4):438-447. Published online November 6, 2020; DOI: https://doi.org/10.5217/ir.2020.00055
Cited By 7; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy: Ryohei Hayashi, Yoshitaka Ueno, Shinji Tanaka, Kana Onishi, Takeshi Takasago, Masaki Wakai, Toshikatsu Naito, Kensuke Sasaki, Shigehiro Doi, Takao Masaki, Kazuaki Chayama; Intest Res. 2021;19(4):430-437. Published online November 9, 2020; DOI: https://doi.org/10.5217/ir.2020.00067
Cited By 1; Full text PubReader ePub Crossref - TDM PDF Graphic abstract

Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study: Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, Mariko Kobayashi, Toshifumi Hibi; Intest Res. 2021;19(4):419-429. Published online November 10, 2020; DOI: https://doi.org/10.5217/ir.2020.00033
Cited By 12; Full text PubReader ePub Crossref - TDM PDF

Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study: Tadakazu Hisamatsu, Yasuo Suzuki, Mariko Kobayashi, Takashi Hagiwara, Takeshi Kawaberi, Haruhiko Ogata, Toshiyuki Matsui, Mamoru Watanabe, Toshifumi Hibi; Intest Res. 2021;19(4):408-418. Published online November 20, 2020; DOI: https://doi.org/10.5217/ir.2020.00025
Cited By 10; Full text PubReader ePub Crossref - TDM PDF

Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease: Rupa Banerjee, Partha Pal, Zaheer Nabi, Upender Shava, Girish Ganesh, D. Nageshwar Reddy; Intest Res. 2021;19(4):398-407. Published online November 20, 2020; DOI: https://doi.org/10.5217/ir.2020.00107
Cited By 10; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI): Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, Yoshifumi Ohnishi, Noriyuki Fujii, Nobuko Matsushima, Richuan Zheng, Colleen W. Marano; Intest Res. 2021;19(4):386-397. Published online December 1, 2020; DOI: https://doi.org/10.5217/ir.2020.00080
Cited By 14; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Patterns of endoscopy during COVID-19 pandemic: a global survey of interventional inflammatory bowel disease practice: Yan Chen, Qiao Yu, Francis A. Farraye, Gursimran S. Kochhar, Charles N. Bernstein, Udayakumar Navaneethan, Kaicun Wu, Jie Zhong, David A. Schwartz, Hao Wu, Jing-Jing Zheng, Marietta Iacucci, Ravi P. Kiran, Bo Shen; Intest Res. 2021;19(3):332-340. Published online June 2, 2020; DOI: https://doi.org/10.5217/ir.2020.00037
Cited By 7; Full text PubReader ePub Crossref - TDM PDF

Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis: Shin Ju Oh, Ga Young Shin, Hosim Soh, Jae Gon Lee, Jong Pil Im, Chang Soo Eun, Kang-Moon Lee, Dong Il Park, Dong Soo Han, Hyo Jong Kim, Chang Kyun Lee; Intest Res. 2021;19(3):323-331. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00039
Cited By 19; Full text PubReader ePub Crossref - TDM PDF

Incidence and risk factors for venous thrombosis among patients with inflammatory bowel disease in China: a multicenter retrospective study: Jing Liu, Xiang Gao, Ye Chen, Qiao Mei, Liangru Zhu, Jiaming Qian, Pinjin Hu, Qian Cao; Intest Res. 2021;19(3):313-322. Published online November 25, 2020; DOI: https://doi.org/10.5217/ir.2020.00017
Cited By 4; Full text PubReader ePub Crossref - TDM PDF

Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study: Yasuo Suzuki, Takashi Hagiwara, Mariko Kobayashi, Kazuo Morita, Tomoyo Shimamoto, Toshifumi Hibi; Intest Res. 2021;19(3):301-312. Published online August 20, 2020; DOI: https://doi.org/10.5217/ir.2020.00013
Cited By 13; Full text PubReader ePub Crossref - TDM PDF Supplementary Material Graphic abstract

Efficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn’s disease: Sanchit Sharma, Arti Gupta, Saurabh Kedia, Samagra Agarwal, Namrata Singh, Sandeep Goyal, Saransh Jain, Vipin Gupta, Pabitra Sahu, Sudheer Kumar Vuyyuru, Bhaskar Kante, Raju Sharma, Rajesh Panwar, Peush Sahni, Govind Makharia, Vineet Ahuja; Intest Res. 2021;19(3):291-300. Published online May 26, 2020; DOI: https://doi.org/10.5217/ir.2019.09172
Cited By 9; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Trends of inflammatory bowel disease at a tertiary care center in northern India: Ajit Sood, Kirandeep Kaur, Arshdeep Singh, Vandana Midha, Ramit Mahajan, Namita Bansal, Varun Mehta, Dharmatma Singh; Intest Res. 2021;19(3):282-290. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00010
Cited By 9; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Prospective validation of CD4⁺CD25⁺FOXP3⁺ T-regulatory cells as an immunological marker to differentiate intestinal tuberculosis from Crohn’s disease: Ritika Rampal, Saurabh Kedia, Mohamad Nahidul Wari, Deepak Madhu, Amit Kumar Singh, Veena Tiwari, V. Pratap Mouli, Srikant Mohta, Govind Makharia, Vineet Ahuja; Intest Res. 2021;19(2):232-238. Published online May 8, 2020; DOI: https://doi.org/10.5217/ir.2019.09181
Cited By 9; Full text PubReader ePub Crossref - TDM PDF

IBD